Plasma YKL-40 levels in healthy subjects from the general population

Clinica Chimica Acta

Volumn 412, Issue 9-10, 2011, Pages 709-712

  Bojesen, Stig E ^a,b   Johansen, Julia S ^a   Nordestgaard, Børge G ^a,b  

^a Mental Health Services CPH   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Biomarkers; CHI3L1; Reference levels; YKL 40

Indexed keywords

GLYCOPROTEIN; UNCLASSIFIED DRUG; YKL 40 PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD ANALYSIS; DENMARK; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; FEMALE; GLYCOPROTEINS; HEALTH; HUMANS; LECTINS; MALE; MIDDLE AGED; REFERENCE VALUES; TIME FACTORS; YOUNG ADULT;

EID: 79951726251     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.01.022     Document Type: Article

References (17)

1. Johansen J.S., Bojesen S.E., Tybjærg-Hansen A., Mylin A., Price P.A., Nordestgaard B. Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 2010, 56:1580-1591.
2. Kjaergaard A.D., Bojesen S.E., Johansen J.S., Nordestgaard B.G. Elevated plasma YKL-40 levels and ischemic stroke in the general population. Ann Neurol 2010, 68:672-680.
3. Johansen J.S., Bojesen S.E., Mylin A.K., Frikke-Schmidt R., Price P.A., Nordestgaard B.G. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 2009, 27:572-578.
4. Johansen J.S., Schultz N.A., Jensen B.V. Plasma YKL-40: a potential new cancer biomarker?. Rev Future Oncol 2009, 5:1065-1082.
5. Kastrup J., Johansen J.S., Winkel P., et al. High serum YKL-40 concentration in patients with stable coronary artery disease is associated with increased risk of myocardial infarction, cardiovascular death, and all-cause mortality. Eur Heart J 2009, 30:1066-1072.
6. Nielsen A.R., Erikstrup C., Johansen J.S., et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes 2008, 57:3078-3082.
7. Letuve S., Kozhich A., Arouche N., et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008, 181:5167-5173.
8. Fontana R.J., Dienstag J.L., Bonkovsky H.L., et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010, 59:1401-1409.
9. Chupp G.L., Lee C.G., Jarjour N., et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007, 357:2016-2027.
10. Mizoguchi E., Mizoguchi A. Is the sugar always sweet in intestinal inflammation?. Immunol Res 2007, 37:47-60.
11. Johansen J.S., Lottenburger T., Nielsen H.J., et al. Diurnal, weekly and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomark Prev 2008, 17:2603-2608.
12. 3, Leu33Pro homozygosity and risk of cancer. J Natl Cancer Inst 2003, 95:1150-1157.
13. Dahl M., Tybjærg-Hansen A., Schnohr P., Nordestgaard B.G. A population-based study of morbidity and mortality in mannose-binding lectin deficiency. J Exp Med 2004, 199:1391-1399.
14. Zacho J., Tybjærg-Hansen A., Jensen J.S., Grande P., Sillesen H., Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008, 359:1897-1908.
15. Juel K., Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull 1999, 46:354-357.
16. Storm H.H., Michelsen E.V., Clemmesen I.H., Pihl J. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997, 44:535-539.
17. Harvey S., Weisman M., O'Dell J., et al. Chondrex: new marker of joint disease. Clin Chem 1998, 44:509-516.